Search

Search results

399 results found

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.

Kimball, Alexa B, Kenneth B Gordon, Richard G Langley, Alan Menter, Renee J Perdok, Joaquin Valdes, and ABT-874 Study Investigators. 2011. “Efficacy and Safety of ABT-874, a Monoclonal Anti-Interleukin 12/23 Antibody, for the Treatment of Chronic Plaque Psoriasis: 36-Week Observation/Retreatment and 60-Week Open-Label Extension Phases of a Randomized Phase II Trial.”. Journal of the American Academy of Dermatology 64 (2): 263-74.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

Reich, Kristian, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, et al. 2017. “Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and ReSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials.”. Lancet (London, England) 390 (10091): 276-88.